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Objective: Mucosal melanoma is an aggressive malignancy with a poor response to
conventional therapies. The efficacy of radiotherapy (RT), especially combined with
immune checkpoint inhibitors (ICIs), for this rare melanoma subtype remains unknown.
We investigated the reciprocal effect of RT and ICI on mucosal melanoma patients.
Materials and Methods: We identified 23 patients with 31 tumors who were treated
with RT between July 2008 and February 2017. All patients received RT for primary or
metastatic gross tumor mass with a median dose of 4Gy per fraction (range 1.8–12Gy).
Eleven patients (14 lesions) were treated with RT alone, whereas 12 (17 lesions) were
administered pembrolizumab combined with RT (ICI+RT group). The local control (LC)
and adverse event (AE) rates were compared between the groups. Eight patients with
metastatic mucosal melanoma treated with ICI alone during the same study period were
included as a comparison group.
Results: The median follow-up period was 17.4 (range 3.7–95.2) months. The target
lesion control rate at 1-year was significantly higher in the ICI+RT group than in the
RT-alone group or ICI-alone group (94.1% vs. 57.1% vs. 25%; P < 0.05). No abscopal
effect was observed in our cohort. Treatment-related AEs were not significantly increased
in the combined treatment group compared with the RT-alone group (P> 0.05). No grade
≥3 AEs occurred in the ICI+RT group.
Conclusions: Besides RT acting as an immune adjuvant, ICI might have a
radiosensitizing effect and may increase LC without severe toxicity. We have initiated
a phase II study to determine the effects of RT in patients with melanoma undergoing
anti-PD1 (NCT04017897).
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INTRODUCTION
Mucosal melanoma is a rare malignancy, accounting for only 1–
4% of all melanomas (1, 2). It originates from melanocytes in the
mucosal surfaces of the nasal sinuses, oral cavity, vagina, anus,
and other areas. Mucosal melanoma has a behavioral pattern that
is distinct from that of cutaneous melanomas. Besides its distinct
presentation, mucosal melanoma has an aggressive prognosis,
given its high rates of local failure and distant metastasis (3, 4).
The overall 5-year survival rate is low, ranging from 20 to 30%
(5, 6). As for cutaneous melanoma, wide surgical resection is the
primary treatment of choice for localized mucosal melanoma.
Historically, melanoma was regarded as being resistant to
conventional RT (7), although this aspect remains controversial.
Concerning the treatment of mucosal melanoma, a few studies
have reported improved local control (LC) with postoperative RT
use (8–10). However, the role of RT remained limited before the
introduction of immune checkpoint inhibitors (ICIs). Systemic
chemotherapy for improving treatment outcomes in mucosal
melanoma remains unknown.
In the immunotherapy era, conventional assumptions
regarding RT for melanoma have been challenged. Recently, ICIs
have become the major treatment modality for some cancers,
most distinguishably, malignant melanoma. Ipilimumab (an
anti-cytotoxic T-lymphocyte antigen-4 antibody), nivolumab,
and pembrolizumab (an anti-programmed-death 1 monoclonal
antibody) were approved by the United States Food and Drug
Administration for advanced melanoma patients (11–13).
Despite the advent of ICIs, numerous patients do not respond
to ICI and develop adverse events (AEs). Preclinical and clinical
studies suggest that RT induces a systemic immune response
to tumors outside of the radiation target (14–16). However,
data analyzing the reciprocal radiosensitizing effects of ICI on
LC are scarce. Furthermore, the efficacy of ICI with RT for
mucosal melanoma, a rarer and more radioresistant entity of
melanoma, remains unknown. We aimed to investigate the
efficacy and safety of RT combined with pembrolizumab in
mucosal melanoma patients.
METHODS
Study Population
Patients treated for mucosal melanoma between July 2008
and December 2018 were identified from our institutional
database. Mucosal melanomas were tumors arising frommucous
membranes, such as those in the head and neck, anorectum,
female genital tract, and urinary tract. Ocular melanomas,
including tumors involving the conjunctiva and uvea, were
excluded. Histological confirmation of the lesion was essential
for all cases. We included patients receiving RT for gross tumor
lesions, either at the primary site or a metastatic lesion. Among
33 patients, those not completing RT (n = 5) and lost to follow-
up (n = 5) were excluded. Ultimately, 23 patients treated for 31
lesions were included. During the study period, at our institution,
we then included 8 patients treated with ICI alone for mucosal
melanoma to investigate the possibility of an effect of ICI on
local control.
Clinical information regarding demographic data, subsite
of origin, staging, surgical resection, adjuvant treatment, and
outcome was retrieved. All patients were staged according to the
7th American Joint Committee on Cancer staging system for
each anatomical site, given that there is no staging system that
can integrate staging of mucosal melanoma. Metastasis staging
was based on cutaneous melanoma criteria. This retrospective
study was reviewed and approved by the institutional review
board of the Yonsei University Health System (IRB 4-2017-1187).
The patient records/data were anonymized and de-identified
before analysis, and the requirement for informed consent
was waived.
Treatment
At our institution, the basic treatment principle for patients
without distant metastasis at presentation was primary surgical
resection if the lesion was resectable, followed by adjuvant
interferon therapy, chemotherapy, or adjuvant RT. Adjuvant
treatment was decided upon according to the disease extent
and clinician’s judgment. For patients diagnosed with stage
IV disease, chemotherapy with dacarbazine was primarily
considered before the ICI era. ICI became the first-line
treatment after its approval for metastatic melanoma patients.
Pembrolizumab (Keytruda R©, Merck), an anti-programmed cell
death-1 (PD-1) antibody, was administered intravenously at 2
mg/kg doses every 2 or 3 weeks. Local RT was considered
if a solitary gross mass or symptomatic lesion existed. The
radiation dose was determined depending on the anatomic site
and indication. The median dose of radiation was 40 (range
20–69) Gy, with a median fractional dose of 4 (range 1.8–12)
Gy. Pembrolizumab and RT administered to any lesion was
considered concurrent treatment if RT was performed within 4
weeks after initiating or ending ICI; all other approaches were
defined as non-concurrent treatment.
Follow-Up
Patients were medically evaluated before administering
pembrolizumab. During RT, all patients were examined once a
week. Acute toxicities were recorded and graded according to
the Common Terminology Criteria for Adverse Events (v4.01).
After completing the scheduled treatment, regular follow-up
was conducted every 1–3 months with imaging studies. All
treated lesions were measured according to the Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1 by computed
tomography or magnetic resonance imaging, as available;
complete response (CR): disappearance of all target lesions;
partial response (PR): ≥30% decrease in the sum of the largest
diameters of the target lesions, relative to baseline; progressive
disease (PD): ≥20% increase in the sum of the largest diameters
of the target lesions, relative to the sum of the smallest diameter
recorded, or the appearance of one or more new lesions; or stable
disease (SD): neither PR nor PD (17). For patients treated with
ICI alone, the response was evaluated according to the immune
RECIST criteria (18). The objective response rate (ORR) was
defined as the proportion of patients achieving CR or PR.
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Statistical Analysis
To compare patient demographics, P values were determined
using the X2 test or Fisher’s exact test for categorical variables
and one-way analysis of variance for continuous variables. The
primary endpoints were LC rates and AEs in mucosal melanoma
patients treated with RT ± pembrolizumab or ICI alone. The
secondary endpoints were progression-free survival (PFS) and
overall survival (OS). Each endpoint was compared between the
groups (ICI+RT vs. RT alone vs. ICI alone). PFS was determined
from the date of initiating RT to the corresponding event,
whereas OS was calculated from the date of diagnosis to the date
of death or loss to follow-up. The Kaplan–Meier method with the
log-rank test was used to analyze survival outcomes. All statistical
tests were two-sided, with significance defined as P < 0.05. All
data were analyzed using IBM SPSS software version 23.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Overall, 31 patients were analyzed in this study. Four patients
received RT for two lesions each, and two patients, for three
lesions sequentially. Eleven patients with 14 lesions and 12
patients with 17 lesions were included in the RT alone and
ICI+RT groups, respectively. Eight patients were included in ICI
alone group. Details on patient and treatment characteristics are
summarized in Tables 1, 2.
Patients Treated With Radiotherapy Alone
Eleven patients were treated with RT alone for 14 lesions,
including 5 primary sites and 9 metastatic lesions. The median
age was 48 (range 39–73) years. Subtype of mucosal melanoma
was head and neck in 8 (72.7%) and anorectum in 3 patients
(27.3%). Six (54.5%) patients previously received resection for a
primary lesion. Six (54.5%) patients received one or more prior
lines of systemic therapy for advanced disease. The radiation dose
was a median of 3Gy (range 2–12) per fraction and a median of
45Gy (range 20–69) in total. BRAF mutation status was reported
in 4 (36.4%) patients, and one had a BRAF mutation.
Patients Treated With Radiotherapy
Combined With Immune-Checkpoint
Inhibitor
Twelve patients were administered pembrolizumab combined
with RT, concurrently in 11 patients and sequentially in 1
patient for whom pembrolizumab was administered 7 months
before initiating RT. The median interval between the first
administration of pembrolizumab and initiating RT was 9 (range
0–214) days. The number of treated lesions were 17, including
7 primary and 10 metastatic lesions. The median age was 58
(range 32–81) years. Subtype was head and neck in 5 (41.7%),
anorectum in 4 (33.3%), and genitourinary tract in 3 (25%)
patients, respectively. Radiation dose was median 5Gy (range
1.8–8) per fraction and median 36Gy (range 20–60) in total. A
BRAF mutation was reported in half of the patients in whom no
BRAF mutation was detected.
TABLE 1 | Patient characteristics.
RT alone ICI+RT ICI alone Total p
(N = 11) (N = 12) (N = 8) (N = 31)
Sex 0.820
Male 5 (45.5%) 2 (16.7%) 3 (37.5%) 10 (32.3%)
Female 6 (54.5%) 10 (83.3%) 5 (62.5%) 21 (67.7%)
Age, year 55.0 ± 12.2 58.5 ± 15.1 59.5 ± 8.6 55.1 ± 13.2 0.438
Subtype 0.012
H&N 8 (72.7%) 5 (41.7%) 7 (87.5%) 20 (64.5%)
Anorectum 3 (27.3%) 4 (33.3%) 1 (12.5%) 8 (25.8%)
Genitourinary
tract
0 (0.0%) 3 (25.0%) 0 (0.0%) 3 (9.7%)
BRAF
mutation
0.167
No 3 (27.3%) 6 (50.0%) 5 (62.5%) 14 (45.2%)
Yes 1 (9.1%) 0 (0.0%) 0 (0.0%) 1 (3.2%)
Unknown 7 (63.6%) 6 (50.0%) 3 (37.5%) 16 (51.6%)
C-kit mutation
No 2 (18.2%) 4 (33.3%) 3 (37.5%) 9 (29.0%)
Unknown 9 (81.8%) 8 (66.7%) 5 (62.5%) 22 (71.0%)
LDH (IU/L) 190.4 ± 38.5 422.3 ± 749.2 164.5±13.4 299.6 ± 521.9 0.547
Resection 1.000
No 5 (45.5%) 5 (41.7%) 8 (100%) 10 (43.5%)
Yes 6 (54.5%) 7 (58.3%) 0 (0.0%) 13 (56.5%)
Adjuvant IFN 1.000
No 10 (90.9%) 11 (91.7%) 21 (91.3%)
Yes 1 (9.1%) 1 (8.3%) 2 (8.7%)
No. of treated
lesion
14 (35.9%) 17 (43.6%) 8 (20.5%) 39 (100%)
RT site* 1.000
Primary 5 (35.7%) 7 (41.2%) 12 (38.7%)
Metastasis 9 (64.3%) 10 (58.8%) 19 (61.3%)
Total dose,
Gy (range)*
45 (20–69) 36 (20–60) 40 (20–69) 0.034
Fractional
dose, Gy
(range)*
3 (2–12) 5 (1.8–8) 4 (1.8–12) 0.315
EQD2, Gy
(range)*
48 (24–88) 44 (31.3–62) 46 (24–88) 0.051
LDH, lactate dehydrogenase; RT, radiotherapy; IFN, interferon; EQD2, equivalent dose in
2Gy fractions.
*Lesion-by-lesion analysis.
Patients Treated With Immune-Checkpoint
Inhibitor Alone
Eight patients were diagnosed with stage IV disease and received
ICI as the first treatment, except two patients who previously
performed first-line chemotherapy. Six patients administered
pembrolizumab and two patients received ipilimumab. The
median age was 59 (range 48–73) years and all patients had
head and neck subtype except for 1 patient who had anorectal
melanoma. No BRAF mutation was detected among 5 patients
whose mutation status was known.
Infield LC and Response Rate
The median follow-up period was 17.4 (range 3.7–95.2) months.
The median follow-up periods were 14 (range 3.7–95.2), 21.9
(range 9.2–56.9), and 9 (range 4–35) months for the ICI+RT,
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TABLE 2 | Detailed characteristics of patients treated with radiotherapy.
No Primary BRAF c-kit LDH (IU/L) Initial M stage Previous
treatment
Site
irradiated
ICI RT dose RT
technique
Best
response
Outfield
response
1 Maxilla NR NR 194 M1 DTIC/IFN Primary site No 60 Gy/30fx IMRT PR PD
2 Nasal cavity NR NR 164 M0 DTIC/IFN Primary site No 69 Gy/23fx IMRT PR PD
3 Nasal cavity NR NR 231 M0 Resection +
PORT
Sacrum No 20 Gy/5fx IMRT SD PD
4 Nasopharynx WT WT 119 M0 No Primary site No 64 Gy/32fx IMRT PR PD
5 Rectum WT NR 200 M1 No Primary site No 45 Gy/15fx 3D-CRT PR PD
6 Rectum NR NR 195 M1 No Brain No 45 Gy/15fx 3D-CRT SD PD
7 Buccal mucosa NR NR 2,013 M0 Multiple resection,
DTIC
Rt. cheek
mass
No 39 Gy/13fx IMRT PD PD
8 Anus WT WT 187 M0 Resection +
PORT
Rt. humerus,
Lt. scapula
Pembrolizumab 37.5 Gy/5fx,
40 Gy/10fx
3D-CRT SD, SD PD
9 Nasal cavity Codon 601 WT 183 M0 Resection +
PORT, DTIC,
Taxol/carbo
Liver,
mediastinal
LN,
abdominal
nodule
No 45 Gy/15fx,
40 Gy/10fx,
40 Gy/10fx
IMRT SD, SD, PR PD
10 Nasal cavity WT NR 204 M0 Multiple resection,
DTIC
Neck node No 66 Gy/30fx IMRT PR PD
11 Anorectal NR NR 143 M0 Resection Paravertebral
muscle, Lt.
paravertebral
muscle, Rt.
No 40 Gy/10fx,
40 Gy/10fx
3D-CRT PR, SD PD
12 Maxilla NR NR 201 M0 Resection Recurrent
neck node
Pembrolizumab 50 Gy/25fx IMRT PR PD
13 Buccal mucosa NR NR 258 M0 DTIC, Taxol/carbo Primary site No 50 Gy/20fx IMRT PR PD
14 Vulva NR NR 2,799 M0 MMS, wide
excision
Pelvic nodule Pembrolizumab 45 Gy/25fx 3D-CRT PR PD
15 Anorectal WT NR 215 M0 Resection Abdominal
nodule
Pembrolizumab 20 Gy/10fx 3D-CRT SD SD
16 Vulva WT WT 212 M0 Resection, IFN,
DTIC, Taxol/carbo
Spleen Pembrolizumab 40 Gy/10fx 3D-CRT SD PD
17 Nasal cavity NR NR 145 M1 No Primary site Pembrolizumab 60 Gy/25fx IMRT PR PD
18 Nasal cavity WT WT 191 M0 Resection Primary site Pembrolizumab 59.2 Gy/27fx IMRT PR PD
19 Vagina WT WT 203 M0 No Primary site Pembrolizumab 36 Gy/6fx IMRT CR SD
20 Rectum NR NR 229 M1 No Primary site,
pancreatic
mass, lung
Pembrolizumab 30 Gy/6fx, 25
Gy/5fx, 30
Gy/6fx
IMRT SD, PR, SD PD
21 Urethra WT WT 166 M0 No Primary site,
inguinal LN
Pembrolizumab 30 Gy/6fx, 30
Gy/6fx
3D-CRT PR, PR SD
22 Nasal cavity NR NR 249 M0 Resection Primary site Pembrolizumab 55 Gy/25fx IMRT PR SD
23 Vulva NR NR 271 M0 Resection Primary site,
lung
Pembrolizumab 30 Gy/6fx, 24
Gy/8fx
IMRT SD, SD PD
LDH, lactate dehydrogenase; ICI, immune checkpoint-inhibitor; RT, radiotherapy; fx, fractions; WT, wild type; NR, not reported.
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RT-alone, and ICI-alone groups, respectively. The 1-year LC rate
was 94.1, 57.1, and 25% for the ICI+RT, RT-alone, and ICI-alone
groups, respectively, and was significantly better in the ICI+RT
combination group (P < 0.005; Figure 1). Of 31 lesions treated
with RT, 1 showed CR and 16 showed PR, for an infield ORR of
54.8%. SD and PDwere observed in 13 and 1 lesions, respectively.
The infield ORRs were similar for the ICI+RT and RT-alone
groups (52.9% vs. 57.1%; P = 0.815). However, once obtained,
the response was maintained longer in the ICI+RT group than in
the RT-alone group, although the follow-up period was relatively
short in the ICI+RT group (Figure 2). The target lesion volume
of the ICI+RT group showed decreasing tendency, whereas
changes in the target lesion volume of the RT-alone group varied.
Among 8 patients treated with ICI alone, 6 experienced PD and
2 had CR, with an ORR of 25%. The waterfall plot for all patients
is illustrated in Figure 3.
Treatment-Related Adverse Events
Radiation-related adverse events were observed in 12 (52.2%)
of 23 patients (Table 3). Overall, the most frequently reported
AE was Grade 1 or 2 fatigue. Grade 3 AEs were reported
by 3 (13.0%) patients, including G3 mucositis in 2 and G3
gastrointestinal disorder in 1 patient. There was no Grade 4
or higher treatment-related AE. All AEs were transient and
manageable with conservative management. Regarding AEs
based on treatment sites, 8/12 patients were treated for their
primary lesions, whereas 4 were treated for the metastatic mass
located in the abdominopelvic area. The combination of RT and
pembrolizumab did not increase AE incidence. No statistically
significant differences existed in the incidence of any AEs
between the two groups. Among patients treated with ICI alone,
there was no grade 3 or higher AE observed.
Survival Outcomes
The 1- and 2-year OS rates were 90.4 and 56.0%, respectively, for
all patients. The 2-year OS rates were 85.7, 42.9, and 65.6% for the
FIGURE 1 | Comparison of the 1-year local control rates of the target lesion in
three treatment groups (ICI+RT vs. RT alone, 94.1% and 57.1%; p = 0.028,
ICI+RT vs. ICI alone, 94.1% vs. 25%; p < 0.001). ICI, immune checkpoint
inhibitors; RT, radiotherapy; ICI+RT, pembrolizumab combined with RT.
ICI+RT, RT-alone, and ICI-alone groups, respectively; however,
the difference was not statistically significant (P = 0.095;
Figure 4). The 1-year PFS rates were 0, 7.1, and 25.0% for
the ICI+RT, RT-alone, and ICI-alone groups, respectively
(P = 0.727; Figure 4). Almost all patients experienced outfield
tumor progression during the follow-up period. No abscopal
effect was observed in our cohort. Clinical factors including
gender, age, subtype, and lactate dehydrogenase were not
significantly associated with OS or PFS. We could not include
BRAF and c-kit mutations in the analysis as the mutational status
was not reported in more than half of the patients.
DISCUSSION
Mucosal melanoma has biological and epidemiological features
distinct from those of cutaneous melanoma. In the management
of cutaneous melanoma, a remarkable evolution has recently
occurred with the introduction of ICI. Response rates have
improved (20–45%) in metastatic melanoma patients treated
with anti-PD-1 monotherapy (12, 18, 19). However, because of
its rarity, only a few studies have investigated the efficacy of ICI
in mucosal melanoma (20–22). Shoushtari et al. revealed that the
ORR of anti-PD-1 agents nivolumab or pembrolizumab was 23%
in mucosal melanoma patients, with a median PFS of 3.9 months,
which was comparable to previously published rates in cutaneous
melanoma patients (20). D’Angelo et al. isolated a mucosal
melanoma subtype from cutaneous melanoma and revealed that
metastatic mucosal melanoma patients benefitted from ICI (22).
Altogether, the current evidence implies that the response rate
for ICI may not be different in mucosal melanoma, although the
overall prognosis is poorer for mucosal melanoma patients.
To improve ICI efficacy, it is combined with other
treatment modalities, and RT can be one of optimal candidate.
Among various cancer histologies, melanomas are intrinsically
radioresistant, as shown by cell culture studies (23). Interestingly,
recent evidence suggests the possibility that immunity could
also affect LC. Lee et al. found that RT induced upregulation
of the immune response by increasing T-cell infiltration into
the tumor microenvironment (TME), which induced significant
tumor regression in wild-type mice, whereas tumors remained
radioresistant to RT in nude mice, in which T cells were
absent (24). This result suggests that the immune system is
crucial for eliciting therapeutic effects of RT. Furthermore, in
radioresistant tumors, namely, melanoma, whether the activation
of the immune system improves the clinical efficacy of RT in
terms of LC needs to be clarified.
For mucosal melanoma, wide surgical excision is the only
effective approach to control macroscopic disease spread, and
RT may be used selectively to control the microscopic disease.
Several series have reported a suboptimal LC rate with RT
alone in unresectable mucosal melanoma cases. The Northern
Japan Radiation Therapy Oncology Group reported about 31
patients treated with definitive RT using a 50-Gy median dose for
unresectable head and neck mucosal melanoma. The CR and PR
rates were 29 and 58%, respectively, with a tumor control rate of
61% (25). Another study showed a 3-year actuarial LC rate of 49%
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FIGURE 2 | Changes in tumor volumes over time after radiation in the (A) RT-alone and (B) ICI+RT groups. ICI, immune checkpoint inhibitors; RT, radiotherapy;
ICI+RT, pembrolizumab combined with RT.
FIGURE 3 | Waterfall plot of best responses of all lesions according to the treatment groups.
using a radiation dose of 50–55Gy in 15–16 fractions (26). In a
randomized study comparing the effectiveness of two different
RT schedules in treating soft-tissue and nodal metastasis, the
ORR was 59% and CR rate was 24% (27). In our study, the
ORR for RT was 54.8% for all gross lesions, which is similar to
previous results. The response rate of RT is high by itself, given
that the response rate in the previously reported melanoma trials
of PD-1 blockade with nivolumab or pembrolizumab was 23–
31% (22, 28, 29). RT may be a good treatment modality for LC
when the tumor is unresectable, as is common in clinical practice.
Various preclinical studies have demonstrated that RT
interacts with the immune system (14, 30, 31). This interaction
can stimulate and suppress the immune system, depending
on the radiation volume, dose fraction size, and tumor
environment. RT causes the death of tumor cells and improves
the ability of the immune system to recognize tumors by
releasing tumor-associated antigens and immunostimulatory
compounds within the tumor (14, 16). Sub-ablative doses
of RT could increase dendritic cell activation and T-cell
priming, and low-dose radiation can increase tumor-infiltrating
lymphocytes by breaking down the stroma and inducing
macrophage differentiation. Thus, the invasion of primed CD8+
T cells and other effector cells into the TME is promoted,
providing a localized antitumor immune response. Furthermore,
as previously reported in 2012 (32), immune effector cells locally
primed by RT recognize and destroy tumors in non-irradiated
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TABLE 3 | Radiation-related adverse events.
Adverse events
RT alone (N = 11) ICI+RT (N = 12) P value
CTCAE category Gr 1 Gr 2 Gr 3 Gr 4+ All (%) Gr 1 Gr 2 Gr 3 Gr 4+ All (%)
General disorders (Fatigue, anorexia) 6 0 0 0 6 (54.5) 2 2 0 0 4 (33.3) 0.305
Gastrointestinal disorders 0 1 1 0 2 (18.2) 1 2 0 0 3 (25.0) 1.000*
Oral mucositis 0 2 2 0 4 (36.4) 1 1 0 0 2 (16.7) 0.371*
Xerostomia 0 3 0 0 3 (27.3) 1 1 0 0 2 (16.7) 0.640*
Hepatobiliary disorders 0 0 0 0 0 (0.0) 1 0 0 0 1 (8.3) 1.000*
Skin and subcutaneous tissue disorders 0 0 0 0 0 (0.0) 1 0 0 0 1 (8.3) 1.000*
CTCAE, Common Terminology Criteria for Adverse Events.
*Fisher’s exact test.
FIGURE 4 | Kaplan-Meier curves for (A) progression-free survival and (B) overall survival of the ICI+RT, RT alone, and ICI alone groups. ICI, immune checkpoint
inhibitors; RT, radiotherapy; ICI+RT, pembrolizumab combined with RT.
sites that share the same antigens they are primed against—an
abscopal effect.
Considering these effects of RT on immune system function,
both locally and systemically, studies have focused on the
clinical implication of RT combined with systemic ICI, which
reverses the immunosuppressive effect of tumors, thus facilitating
anti-tumor immunity together with RT. A few studies have
reported the outcomes of combination treatment for cutaneous
melanoma. Hiniker et al. reported that 11 of 22 patients
treated with ICI+RT experienced better than SD, suggesting
that a subset of patients benefit from combination therapy (33).
Twyman-Saint Victor et al. reported that 18% of 22 patients had
PR in a non-irradiated site when treated with hypofractionated
RT followed by ipilimumab (34). In our study, despite subablative
or palliative doses, the 1-year LC rate was 94.1% for the ICI+RT
group, which was significantly higher than that for the RT-alone
group, implying a radiosensitizing effect of ICI. Considering
that the 1-year LC rates were 25% in patients treated with
ICI alone, we can suggest that this may not be due to the
effect of ICI alone, further implying a synergistic effect of RT
combined with ICI. However, the number of patients included
in this analysis was very small; thus, future clinical trials are
needed. Unfortunately, we could not assess whether RT had a
synergistic effect on systemic outcomes, given that our study
cohort included heterogeneous clinical situations at RT. In our
study, no abscopal effect was observed, and outfield progression
was not improved by combination with ICI. This result could
be because most lesions were treated with conventional fractions
(67.7%), by which the stimulator of the interferon genes pathway
is not activated and thus interferon levels are not increased
(35). Radiation-induced lymphopenia, which is more frequently
observed in long-course than in short-course RT, might also be
associated with this outcome.Many studies are currently ongoing
to determine the optimal RT dose and site to induce a more
abscopal effect.
Until now, only one study has reported the result of combined
RT and anti-PD-1 therapy in seven mucosal melanoma patients
(36). Regarding response rates, four of seven patients (57.1%)
achieved CR or PR. In our study, three among seven lesions of
the RT+ICI group and 11 among all 21 lesions achieved better
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than PR. This result is similar to or slightly higher than that of
previous reports; however, the strength of our study is that it is
the only study comparing the efficacy of combination therapy to
that of RT alone.
In our study, 3 (13%) patients experienced grade 3 AEs, and
no AE > Grade 4 was observed. Adding pembrolizumab to RT
did not increase the rate of AEs in our patients. This result is
similar to recent evidence from a prospective trial investigating
the safety of multisite stereotactic body radiotherapy (SBRT)
followed by pembrolizumab in metastatic solid tumors (37). The
trial revealed that 10% of 62 patients experienced treatment-
related severe toxicity (≥Grade 2), with a median follow-up of
5.5 months. We can assume that combined ICI+RT might not
synergistically increase treatment-related toxicities, given that
these results are similar to those of SBRT or pembrolizumab
monotherapy. However, more results from a larger number of
patients with long-term follow-up are necessary to ensure the
safety of combined treatment.
Our study has limitations besides its retrospective design.
First, the number of patients included was small. Because of
its rarity, a limited number of studies on mucosal melanoma
patients have been conducted to date, and large randomized
clinical trials are difficult to organize. Second, patients treated
with ICI+RT were recently treated compared to those treated
with RT alone. However, this approach might include little bias
given that the treatment of mucosal melanoma and the RT
technique have not changed that much during this period.
In conclusion, we investigated the effect of RT combined
with ICI on LC in mucosal melanoma patients, especially
comparing combined treatment with RT alone. RT might be
helpful in improving the LC of mucosal melanoma, either in the
primary or metastatic setting. We believe that ICI might have
a radiosensitizing effect and may increase LC without causing
severe toxicity. Further clinical trials are warranted to refine
the role of RT when combined with ICI in mucosal melanoma
patients. We have initiated a phase II study to determine the
effects of RT in Asian patients with melanoma who have more
mucosal type than their Western counterparts undergoing anti-
PD1 (NCT04017897).
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